Results 71 to 80 of about 21,053 (285)

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. [PDF]

, 2017
Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation (AF). Early detection of AF and subsequent initiation of oral anticoagulation help to prevent strokes in AF patients.
Blank, BF, Calvert, M, Camm, AJ, Chlouverakis, G, Diener, H-C, Goette, A, Huening, A, Kirchhof, P, Lip, GYH, Simantirakis, E, Vardas, P   +10 more
core   +2 more sources

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source

Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study

Frontiers in Pharmacology
IntroductionNon–vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy to prevent ischaemic stroke in patients with atrial fibrillation (AF).
Xueyuan Guo, Juan Du, Yuehui Yin, Heng Qi, Zhisheng Jia, Xiaojun Ji, Yuqing Zhang, Xue Liang, Bing Deng, Jieyun Liu, Juan Ma, Cangsang Song, Huifang Feng, Suxin Luo, Jingfeng Wang, Yongqi Xiao, Lun Li, Junyou Cui, Zheng Huang, Xiang Cheng, Yuan Yi, Mengqi Liu, Cathy Chen, Martin Unverdorben, Changsheng Ma   +24 more
doaj   +1 more source

The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation

Атеротромбоз, 2020
Edoxaban is a selective direct factor Xa inhibitor. Edoxaban in a dose of 60 mg per day is an effective and safe option in the prevention of thromboembolic complications in patients with nonvalvular atrial fibrillation, including in combination therapy ...
O. O. Shakhmatova
doaj   +1 more source

A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol. [PDF]

, 2019
BACKGROUND: Treatment with anticoagulants, including direct oral anticoagulants (DOACs), should be considered for patients diagnosed with atrial fibrillation (AF) deemed at risk of ischaemic stroke.
Bhat, Y, Dixit, A, Mistri, A, Patel, B, Quoraishi, SH, Uprichard, J   +5 more
core   +1 more source

Prevalence, contemporary trends and associated factors of potentially inappropriate prescription of edoxaban in real‐world clinical practice: A subanalysis of the SUNSHINE registry

British Journal of Clinical Pharmacology, 2023
As the direct oral anticoagulant most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated the prevalence of and contemporary trends in edoxaban prescription among Chinese patients as well as ...
Shujuan Zhao, Hengfen Dai, Jiaxin Chen, Ming Ni, Wenxing Peng, Xiaoyu Li, Fen Li, Boya Chen, H. Cai, Yinping Liu, Zhichun Gu, Song Du, Peizhi Ma   +12 more
semanticscholar   +1 more source

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy

Case Reports in Critical Care, 2016
Introduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC).
Kenichi Nitta, Hiroshi Imamura, Akihiro Yashio, Satoko Kashima, Katsunori Mochizuki   +4 more
doaj   +1 more source

Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [PDF]

, 2016
A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI). However, incidence and management of MI in AF is still undefined. METHODS AND RESULTS: We searched MEDLINE via PubMed and Cochrane database
PASTORI, DANIELE, PIGNATELLI, Pasquale, Soliman, Elsayed Z, VIOLI, Francesco   +3 more
core   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source